Literature DB >> 6404186

Chagas' disease: a clinical, parasitological, immunological, and pathological study in rabbits.

A R Teixeira, F Figueiredo, J Rezende Filho, V Macêdo.   

Abstract

Thirty-four rabbits were experimentally infected with trypomastigotes of either the Ernestina or the Albuquerque strains of Trypanosoma cruzi. These animals showed patent parasitemias, as demonstrated by xenodiagnosis, in the acute phases of the infections. Typical chagoma signs developed in two rabbits 1 week after parasite inoculation in the skin, although the acute phase of Chagas' disease in the rabbit model was usually asymptomatic. In the 6th month of infection the parasitemias became negative and the infections remained subpatent, as indicated by the persistence of positive serologic tests and of delayed-type skin reactions elicited in Chagas' rabbits against a microsomal T. cruzi antigen. This latent infection continued asymptomatically, in the absence of electrocardiographic (ECG) alterations. However, ECG changes consistent with enlargement and overload of cardiac chambers, alterations of ventricular repolarization, S-T changes and bundle-branch blocks were frequently recorded later in the chronic phase of Chagas' disease. The pathological manifestations of these ECG alterations were confirmed at the autopsy of each experimental rabbit. Congestive heart failure and pulmonary thromboemboli related to chronic myocarditis of Chagas' disease were frequent causes of death. Megacolon was seen in two rabbits inoculated with the Ernestina strain of the parasite. The relatively limited duration of detectable parasitemia even when xenodiagnosis is used, the lack of correlation between parasitemia and severity of pathological manifestations, and the fact that all infected animals showed histopathological evidence of myocarditis, destructive inflammatory lesions characterized by mononuclear infiltrates in skeletal muscles, as well as cutaneous delayed hypersensitivity to T. cruzi antigens, are notable observations in this animal model of the human disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404186     DOI: 10.4269/ajtmh.1983.32.258

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  6 in total

Review 1.  Role of autoantibodies in the physiopathology of Chagas' disease.

Authors:  Emiliano Horacio Medei; José Hamilton Matheus Nascimento; Roberto Coury Pedrosa; Antônio Carlos Campos de Carvalho
Journal:  Arq Bras Cardiol       Date:  2008-10       Impact factor: 2.000

2.  Advances in imaging of animal models of Chagas disease.

Authors:  Linda A Jelicks; Herbert B Tanowitz
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

3.  Chagas' disease in inbred III/J rabbits.

Authors:  A R Teixeira
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

4.  Inheritance of DNA transferred from American trypanosomes to human hosts.

Authors:  Mariana M Hecht; Nadjar Nitz; Perla F Araujo; Alessandro O Sousa; Ana de Cássia Rosa; Dawidson A Gomes; Eduardo Leonardecz; Antonio R L Teixeira
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

Review 5.  White paper on guidelines concerning enteric nervous system stem cell therapy for enteric neuropathies.

Authors:  Alan J Burns; Allan M Goldstein; Donald F Newgreen; Lincon Stamp; Karl-Herbert Schäfer; Marco Metzger; Ryo Hotta; Heather M Young; Peter W Andrews; Nikhil Thapar; Jaime Belkind-Gerson; Nadege Bondurand; Joel C Bornstein; Wood Yee Chan; Kathryn Cheah; Michael D Gershon; Robert O Heuckeroth; Robert M W Hofstra; Lothar Just; Raj P Kapur; Sebastian K King; Conor J McCann; Nandor Nagy; Elly Ngan; Florian Obermayr; Vassilis Pachnis; Pankaj J Pasricha; Mai Har Sham; Paul Tam; Pieter Vanden Berghe
Journal:  Dev Biol       Date:  2016-04-05       Impact factor: 3.582

Review 6.  Translational challenges of animal models in Chagas disease drug development: a review.

Authors:  Eric Chatelain; Nandini Konar
Journal:  Drug Des Devel Ther       Date:  2015-08-19       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.